- May 1
- 11 min read
Updated: May 3
When your child's cancer stops responding to chemotherapy, a doctor may mention CAR-T cell therapy for the first time. The term sounds hopeful — and it often is. But it comes with specific medical criteria your child must meet before treatment can begin.
This guide walks you through every eligibility requirement in plain language: the diagnosis criteria, the test results you need, the questions to ask your oncologist, and what to do if your child doesn't yet qualify.
And when they do qualify — we'll show you exactly how to access treatment at a fraction of the cost through ChinaCureLink's network of 50+ partner hospitals in China.
The 3 Gates Your Child Must Pass for Pediatric CAR-T Eligibility
CAR-T eligibility is a sequence of three clinical gates — each one narrowing the candidate pool. Understanding all three helps you have a more informed conversation with your oncologist and know exactly what information to gather before contacting any treatment center.
GATE | WHAT IS ASSESSED | THE SPECIFIC REQUIREMENT | WHY IT MATTERS |
01 | Diagnosis Type | Must be CD19+ or CD22+ B-cell acute lymphoblastic leukaemia (B-ALL) or B-cell non-Hodgkin lymphoma | CAR-T targets specific proteins. If those proteins aren't on your child's cancer, the therapy has no target and will not work. |
02 | Treatment History | Must have relapsed after ≥2 prior lines of therapy, OR be primary refractory (disease never achieved remission) | CAR-T is approved for when standard treatment has failed. Regulators set this threshold to justify the risk profile of the therapy. |
03 | Physical Fitness | Adequate organ function: heart, liver, kidneys. No active uncontrolled infection. Performance status compatible with intensive therapy. | CAR-T triggers intense immune activation. The child's organs must be strong enough to withstand Cytokine Release Syndrome and its management. |
Does Your Child Have the Right Type of Cancer?
CAR-T therapy approved for pediatric use targets two proteins — CD19 and CD22 — that appear on the surface of certain leukemia and lymphoma cells. Your child's cancer must express at least one for CAR-T to work. This is confirmed by immunophenotyping, a test done at diagnosis that you may already have results for.
Which Diagnoses Qualify?
DIAGNOSIS | MARKER NEEDED | AVAILABLE PRODUCTS | ELIGIBLE? |
B-cell Acute Lymphoblastic Leukaemia (B-ALL) | CD19+ and/or CD22+ | Kymriah, Relma-cel, 50+ trial products in China | ✅ YES |
B-cell Non-Hodgkin Lymphoma (B-NHL) | CD19+ | Kymriah (≥25 kg), Breyanzi (adult, some paediatric use) | ✅ YES |
T-cell ALL (T-ALL) | CD7/CD5 — experimental only | No approved product; trials exist in China | ✗ No |
Acute Myeloid Leukaemia (AML) | CD33 — trials only | Experimental only — no standard approved product | ✗ No |
Hodgkin Lymphoma | CD30 — not CD19/CD22 | CAR-T not standard; niche clinical trials only | ✗ No |
Multiple Myeloma (rare, paediatric) | BCMA / CD38 | Adult products exist; paediatric cases are rare | ◎ Case by case |
CD19 vs CD22: What's the Difference?
CD19 | CD22 | |
What it is | Protein on the surface of most B-cell leukaemia cells. The primary CAR-T target globally. | A different surface protein, also present on most B-ALL cells. Less commonly targeted but increasingly used. |
Key products | Kymriah (Novartis), Relma-cel (CARsgen, China), multiple academic trial products. | CT053, PBCAR22A, and Chinese in-house academic products — strong pipeline, especially in China. |
Risk to know | CD19 can be "lost" after treatment — cancer mutates to hide this protein and evade CAR-T cells. | CD22 is more stable; dual CD19/CD22 products are designed to block this escape route entirely. |
Has Your Child Received Enough Prior Treatment?
CAR-T is not a first-line treatment. It is reserved for children whose cancer has either relapsed after remission, or never responded to standard therapy at all. Here is exactly where in the treatment journey CAR-T eligibility is unlocked.
The Standard Pathway to Pediatric CAR-T Eligibility
LINE | WHAT HAPPENS | TYPICAL OUTCOME | CAR-T DOOR OPEN? |
1st | Diagnosis. Standard induction chemotherapy (e.g. VXLD protocol). Intensive 4–6 week phase. | ~95% of children achieve first remission | ✗ Not yet. First-line must be attempted first. |
2nd | Consolidation + maintenance chemo. 2–3 years of ongoing treatment in remission. | Most remain in remission; 15–20% relapse | ✗ Not yet. Must complete or fail consolidation. |
Relapse 1 | Cancer returns. Salvage chemotherapy begins (FLAG, UKALLR3). Aims for 2nd remission. | Remission in ~60–70% with salvage chemo | Now eligible — 1 relapse after Line 1 qualifies. |
Relapse 2 | Cancer returns again. Salvage options narrow. Disease increasingly chemo-resistant. | 2nd remission rates drop to 30–50% | Strongly eligible — 2 relapses is a clear indication. |
Refractory | Cancer never achieved remission despite induction + ≥1 salvage attempt. Primary refractory. | Very poor prognosis with standard therapy alone | Eligible — primary refractory meets the threshold. |
Documents to Compile Before Applying to Any Center
DOCUMENT | WHY EVERY CENTER WILL ASK FOR IT | WHERE TO GET IT |
Original diagnosis pathology report | Confirms cancer type, subtype, and initial CD19/CD22 immunophenotype status | Treating hospital pathology department |
All bone marrow biopsy results (with dates) | Tracks response to each treatment line and documents each relapse event clearly | Treating oncologist / hematology records |
Chemotherapy treatment summaries | Lists every drug regimen used, duration, and response — defines "lines of therapy" | Oncology clinic — request a formal treatment summary letter |
MRD (Minimal Residual Disease) results | Shows depth of remission at key time points — critical for trial eligibility assessment | Treating oncologist / laboratory reports |
Current disease status report | Confirms active disease burden at time of CAR-T application | Most recent bone marrow biopsy + imaging (within 4–8 weeks) |
Genetic / cytogenetic testing (FISH, NGS) | Identifies high-risk subtypes (Ph+, KMT2A) that affect product choice and protocol | Pathology / molecular diagnostics department |
Is Your Child's Body Strong Enough for CAR-T?
CAR-T causes intense immune activation. The therapy is effective precisely because it triggers a powerful immune response — but that same response puts significant stress on vital organs. Every child must pass a set of organ function tests before treatment begins.
These tests are not obstacles. They are safety checks that protect your child from life-threatening complications during the monitoring phase.
Organ Function Thresholds — What Each Test Looks For
ORGAN | TESTS USED | TYPICAL THRESHOLD | WHY THIS ORGAN |
Heart | Echocardiogram (ECHO) | LVEF ≥45–50% | CRS can cause dangerous drops in blood pressure. A weak heart cannot compensate safely. |
Kidneys | Creatinine, eGFR, urine protein | Creatinine ≤1.5× ULN for age | Kidneys must clear inflammatory markers and drug metabolites during the CRS phase. |
Liver | ALT, AST, bilirubin, albumin | ALT/AST ≤5× ULN; bilirubin ≤2× ULN | The liver processes the cytokine storm. Pre-existing impairment dramatically worsens toxicity risk. |
Lungs | O₂ saturation, chest imaging | O₂ sat ≥92% on room air | Severe CRS can cause pulmonary oedema. Baseline lung function must support this risk. |
Infection | Blood cultures, CRP, fever history | No active uncontrolled infection | Active infection combined with CAR-T immune activation can be rapidly fatal. |
Neurology | Clinical assessment, MRI if needed | No active CNS-only disease (case-dependent) | ICANS (neurotoxicity) risk is elevated in children with existing CNS involvement. |
Note: Exact thresholds vary by institution and clinical trial protocol. The values above are representative of most progress. ChinaCureLink confirms the exact requirements of each partner center before families travel. |
Your Pre-Application Eligibility Checklist
Use this checklist before contacting any CAR-T center. The more boxes you can tick, the faster and smoother the evaluation process will be. ChinaCureLink's team can review your file and complete this assessment for you — free of charge — within 48 hours.
Section A: Diagnosis |
☐ Confirmed B-cell ALL or B-cell NHL (not T-cell ALL, AML, or Hodgkin lymphoma) |
☐ Immunophenotyping report confirming CD19+ and/or CD22+ status |
☐ Cytogenetics / FISH panel completed — identifies high-risk subtypes (Ph+, KMT2A) |
☐ Original diagnostic bone marrow biopsy report available |
Section B: Treatment History |
☐ Child has received ≥2 prior lines of chemotherapy, OR is primary refractory |
☐ Complete chemotherapy treatment summary available (drug names, dates, response per line) |
☐ All bone marrow biopsy reports available with clear relapse documentation |
☐ MRD results from most recent assessment available |
☐ Clear documentation that current disease is relapsed or refractory |
Section C: Current Disease Status |
☐ Most recent bone marrow biopsy (within last 4–8 weeks) |
☐ Imaging results — CT, PET, or MRI — within last 4 weeks |
◎ Disease burden assessed — very high burden may require bridging chemo first (situational) |
☐ No CNS-only disease, or treating centre has been informed of CNS involvement |
Section D: Organ Function |
☐ Echocardiogram performed — LVEF ≥45–50% |
☐ Liver function tests (ALT, AST, bilirubin) within acceptable range |
☐ Kidney function tests (creatinine, eGFR) within range for age |
☐ Oxygen saturation ≥92% on room air — no active pulmonary compromise |
☐ No active uncontrolled infection at time of application |
◎ No prior solid organ transplant (requires individual assessment) (situational) |
Section E: Practical & Logistical Readiness |
☐ Family can travel to and remain at treatment centre for 8–12 weeks |
☐ At least 1–2 caregivers available to accompany child throughout stay |
☐ Funding pathway confirmed — clinical trial, out-of-pocket, or insurance |
☐ Child's home oncologist informed and supportive of international referral |
☐ Passports and travel documents valid for all travelling family members |
✅ Tip: If you tick 80%+ of these boxes, you have a strong file. ChinaCureLink's team will review your complete checklist and tell you which of our 50+ partner hospitals is the best match for your child's profile. |
What to Do If Your Child Doesn't Qualify Right Now
Not every child will clear all three gates immediately. That doesn't mean CAR-T is permanently off the table — it often means there are steps to take first. Here are the most common barriers and the path forward.
BARRIER | WHY IT BLOCKS ELIGIBILITY | PATH FORWARD |
CD19-negative disease | Most approved products require CD19. If absent, standard CAR-T has no target. | ChinaCureLink's network includes centres with active CD22-targeted and dual CD19/CD22 trials — often the only option for this group. |
Only 1 prior line of therapy | Most approvals require ≥2 lines. Regulators require evidence that standard options are exhausted. | Attempt a second salvage chemotherapy line. If disease responds, this also establishes chemo-sensitivity — a positive factor for CAR-T outcomes. |
Organ function below threshold | Heart, liver, or kidney impairment increases CRS complication risk significantly. | Work with the oncology team to optimize organ function. Some cases improve with targeted supportive care, making CAR-T possible 4–8 weeks later. |
Active infection | CAR-T + active infection = very high mortality risk from combined immune activation. | Treat and clear the infection first. Most centers proceed once infection is controlled and the child is stable for 1–2 weeks. |
Very high disease burden | High burden amplifies severe CRS risk. Some centres require partial disease control first. | Bridging chemotherapy or steroids to reduce disease before leukapheresis. ChinaCureLink partner hospitals plan bridging proactively for international families. |
Prior CD19 CAR-T therapy | Cancer may have lost CD19 (antigen escape). A second CD19 CAR-T is unlikely to work. | Request CD19 re-expression testing. Explore CD22 or dual-target options. ChinaCureLink has access to second CAR-T programs in specialized centers. |
Does Age or Weight Affect Eligibility?
Less than most parents expect. The age and weight thresholds for CAR-T are broad, and most children with the right diagnosis fall within them. Here's how it breaks down by product and program — including what's available through ChinaCureLink's partner network.
PRODUCT / PROGRAM | AGE | WEIGHT | NOTES |
Kymriah (Novartis, FDA) | Up to 25 yrs | ≥10 kg recommended | Younger children (under 3) evaluated individually. ChinaCureLink has experience navigating these edge cases. |
China domestic products (Relma-cel etc.) | 1–18 yrs (typical) | No hard minimum; dose weight-adjusted | Chinese academic centres have treated children as young as 12 months. Weight-based dosing makes this more flexible than Western protocols. |
China investigator-initiated trials | 2–18 yrs (varies) | Usually ≥10 kg; some ≥15 kg | Each trial protocol specifies exact criteria. ChinaCureLink pre-screens your child against active trials in our network before you travel. |
Allogeneic (off-the-shelf) trials | 2–18 yrs (varies) | Usually ≥10–15 kg | No leukapheresis required. Particularly relevant when the child is too unwell to collect their own cells. Increasingly available in China. |
8 Questions Every Parent Should Ask at Their Next Appointment
Most oncologists are generalists — not CAR-T specialists. Bringing a structured list of questions is completely appropriate and often results in a much more useful appointment. Here are the twelve that matter most at this stage.
Does my child's leukemia express CD19 or CD22, and can I have a copy of the immunophenotyping report?
Has genetic and cytogenetic testing been completed — specifically for Philadelphia chromosome and KMT2A rearrangement?
Is this confirmed as a relapse of the original disease, or is there a new leukemia subtype present?
How many lines of chemotherapy has my child received, and does this count as relapsed or refractory disease?
Do we have written documentation of each treatment line — drug names, response, and dates?
Is the disease currently responding to treatment at all, or has it stopped responding entirely?
Has my child's heart, liver, and kidney function been tested recently — and are all values within the range required for CAR-T?
Is there any active infection that needs to be cleared before we can apply for CAR-T?
Your Child Qualifies — Here's Exactly What Happens Next
Once you've confirmed eligibility across all three gates, the path to treatment begins. Here is the logical sequence — and where ChinaCureLink steps in to handle the complexity for your family.
STEP | ACTION | WHAT CHINACURELINK DOES AT THIS STAGE | TIMELINE |
01 | Compile your child's complete medical file | Our team sends you a precise document checklist and reviews everything within 48 hours of receipt. | 1–2 weeks |
02 | Remote eligibility assessment | ChinaCureLink's clinical team reviews the file and delivers a written eligibility opinion — which centres, which products, which trials. | 48–72 hours after file receipt |
03 | Hospital matching | We match your child's specific profile — diagnosis, subtype, prior treatment — to the most appropriate centre across our 50+ hospital network. | 3–5 business days |
04 | Funding pathway confirmation | We identify whether your child qualifies for a subsidised trial, commercial treatment, or insurance reimbursement options. Clear cost expectations set upfront. | 1 week |
05 | Medical visa + travel coordination | We liaise with the hospital for the invitation letter, support visa application, and coordinate accommodation near the treatment centre. | 2–3 weeks |
06 | In-hospital coordination + aftercare | ChinaCureLink provides a bilingual coordinator throughout the stay and coordinates post-treatment follow-up with your home oncologist. | 8–12 weeks + ongoing |
Pediatric CAR-T Treatment in China: The Lower-Cost Path to Remission Once you've confirmed eligibility, the natural next question is: where do we go, and how much will it cost? Our companion guide covers hospital options, real pricing ($120K–$180K all-in vs. $600K+ in the US), the treatment process week by week, and how to access clinical trials at near-zero cost. → https://www.chinacurelink.com/post/pediatric-car-t-treatment-in-china |
Frequently Asked Questions
Q1. My child is in remission — can they still get CAR-T? CAR-T is approved for relapsed or refractory disease, so a child in remission does not currently meet standard eligibility. However, some clinical trials — particularly in China — are studying CAR-T as consolidation therapy to prevent relapse. ChinaCureLink can identify whether any active trials match your child's profile. |
Q2. What if my child's cancer is CD19-negative? This is a growing challenge, especially after prior blinatumomab therapy. Options include CD22-targeted CAR-T and dual CD19/CD22 products that capture both proteins simultaneously. China has the world's most active trial pipeline for these alternative targets, and ChinaCureLink's network includes centres with open slots. |
Q3. Can a very young child (under 3) receive CAR-T? Yes, though with added complexity. Very young children have been treated successfully at specialised paediatric centres in China, where dose is weight-adjusted and protocols are paediatric-native. Each case is assessed individually — contact ChinaCureLink and we will identify centres that have experience with very young patients. |
Q4. What if my child's organs are too weak right now? Organ function below threshold is often a temporary barrier. With targeted supportive care, values can improve over 4–8 weeks. ChinaCureLink recommends using this window to prepare your medical file, identify your target centre, and complete the eligibility review so you're ready to move quickly when the window opens. |
Q5. Does prior bone marrow transplant affect eligibility? Prior transplant does not automatically disqualify a child, but it adds complexity. Most programmes require at minimum a 6-month post-transplant interval and no active graft-versus-host disease. Disclose any prior transplant history upfront — ChinaCureLink will flag this to our partner hospitals during the matching process. |
Q6. Can we apply to multiple centres at the same time? Yes, and it's recommended. ChinaCureLink typically presents eligible families to 2–3 matched centres simultaneously, allowing comparison of available products, wait times, and cost structures. This parallel approach significantly reduces total time to treatment. |
About China Curelink
China Curelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
China Curelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Comments